By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Opsona Therapeutics Ltd. 

Ashford House
Tara Street

Second Floor
Dublin    2  Ireland
Phone: 353-1-6770223 Fax: 353-1-6778949


SEARCH JOBS


Industry
Pharmaceutical






Company News
Opsona Announces Preliminary Results From Ongoing Study In Second Line Lower Risk Myelodysplastic Syndrome (MDS) Recently Presented At The 58th Annual Meeting Of American Society of Hematology 12/20/2016 12:56:10 PM
Opsona Receives Orphan Designation For Myelodysplastic Syndrome (MDS) With OPN-305, A First-In-Class Monoclonal Antibody That Blocks Toll-Like Receptor 2 10/25/2016 11:22:21 AM
Opsona Therapeutics Ltd. Commences Part B Of Phase II Study Of Blocking Toll-Like Receptor 2 In Extended Criteria Donor Renal Transplant Recipients At High Risk Of Early Graft Dysfunction 3/2/2015 11:20:17 AM
Opsona Therapeutics Ltd. Patent Issued In USA Covering An Antibody Directed Against Toll-Like Receptor-2 (TLR-2) And The Use And Development Thereof 2/23/2015 10:19:31 AM
Opsona Therapeutics Ltd. Patent Issued In US And EU Covering The Opsona-Developed Antibody OPN-305, Which Is Directed Against Toll-Like Receptor-2 (TLR-2) And The Use And Development Thereof 2/20/2015 12:54:08 PM
Opsona Therapeutics Ltd. Initiates A Prospective Open Label Phase 1/2 Study In Second-Line Lower (Low And Intermediate-1) Risk Myelodysplastic Syndrome (MDS) With OPN-305, A First-In Class Monoclonal Antibody That Blocks Toll-Like Receptor 2 1/26/2015 1:27:04 PM
Opsona Therapeutics Ltd. Initiates A Prospective Open Label Phase 1/2 Study In Second-Line Lower (Low And Intermediate-1) Risk Myelodysplastic Syndrome (MDS) With OPN-305, A First-In Class Monoclonal Antibody That Blocks Toll-Like Receptor 2 1/26/2015 9:31:12 AM
Opsona Therapeutics Ltd. Raises an Additional $4 Million Series C From Omnes Capital 10/2/2013 7:10:30 AM
Opsona Therapeutics Ltd. Initiates a Phase II Study With OPN-305, a First-in Class Monoclonal Antibody That Blocks Toll-Like Receptor 2, in Renal Transplant Patients at High Risk of Delayed Graft Function 5/7/2013 11:19:59 AM
Opsona Therapeutics Ltd. Raises $43 Million to Develop Lead Product 4/29/2013 6:56:26 AM
12
//-->